Cortical Binding of Pittsburgh Compound B, an Endophenotype for Genetic Studies of Alzheimer's Disease

doi:10.1016/j.biopsych.2009.09.012

Biological Psychiatry

Volume 67, Issue 6, 15 March 2010, Pages 581-583

https://doi.org/10.1016/j.biopsych.2009.09.012 Get rights and content

Background

To date, all known Alzheimer's disease genes influence amyloid beta (Aβ). Imaging of Aβ deposition in the human brain using Pittsburgh Compound B (PIB) offers the possibility of using cortical PIB binding as a quantitative endophenotype for genetic studies of late-onset Alzheimer's disease (LOAD).

Methods

Heritability of Aβ deposition was determined using 82 elderly siblings from 35 families. Correlation with other Aβ related traits was determined using an unrelated sample of 112 individuals. For both samples, apolipoprotein E (APOE) ε4 was genotyped and positron emission tomography imaging was performed using the PIB ligand. Mean cortical binding potential (MCBP) was computed from several regions of interest.

Results

MCBP has a high heritability (.61, p = .043). Furthermore, 74% of the heritable component cannot be explained by APOE ε4 genotype. The unrelated sample reveals that a third of the variance of MCBP cannot be predicted by other biological traits, including cerebrospinal fluid (CSF) amyloid beta 42 (Aβ42) levels.

Conclusions

These findings demonstrate that MCBP is a genetic trait and that other more easily measured Aβ related traits such as CSF Aβ42 do not fully explain the variance in MCBP. Thus, MCBP is a useful trait for large-scale genetic studies of LOAD.

Section snippets

Subjects

All subjects gave written informed consent and all studies were approved by the Human Studies Committee of Washington University School of Medicine.

Family Sample

The heritability estimate was .61 with significant p values for both the parametric (p = .043) and empiric (p = .009) tests. We also computed the variance of MCBP explained by number of APOE ε4 alleles, age, gender, and the SBT. The results show highly significant association for APOE and significant association for age and SBT (Table 2). Controlling for just APOE and then controlling for all significant factors yields heritability estimates of .45 and .52, respectively, with nonsignificant

Discussion

The sibship analysis indicates that Aβ deposition as measured by MCBP is a highly heritable trait. We observe significance for both the nominal p value (.043) and the empiric p value (p = .009). We anticipate that the empiric p value is more accurate because of the relatively small sample size; we conservatively report the nominal p value. After controlling for covariates, the trait remains heritable as measured by the empiric p value (p = .034) and 74% of the heritable component of the

References (20)

E.W. Daw et al.
Multipoint oligogenic analysis of age-at-onset data with applications to Alzheimer's disease pedigrees
Am J Hum Genet
(1999)
V.L. Villemagne et al.
Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease
Neuropsychologia
(2008)
R.L. Buckner et al.
A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: Reliability and validation against manual measurement of total intracranial volume
Neuroimage
(2004)
P. Pastor et al.
Molecular genetics of Alzheimer's disease
Curr Psychiatry Rep
(2004)
D. Galasko et al.
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer's disease and relation to apolipoprotein E genotype
Arch Neurol
(1998)
T. Sunderland et al.
Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer's disease
JAMA
(2003)
C.A. Mathis et al.
Synthesis and evaluation of 11c-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents
J Med Chem
(2003)
W.E. Klunk et al.
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B
Ann Neurol
(2004)
A.M. Fagan et al.
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans
Ann Neurol
(2006)
M.A. Mintun et al.
(11C)PIB in a nondemented population: Potential antecedent marker of Alzheimer's disease
Neurology
(2006)

There are more references available in the full text version of this article.

Cited by (24)

Molecular and cellular pathophysiology of preclinical Alzheimer's disease
2016, Behavioural Brain Research
Citation Excerpt :
In AD, CSF Aβ1-42 is reduced and phosphorylated tau is increased, which correlates with post-mortem amyloid and NFT pathology [167]. A strong concordance between PiB PET and CSF Aβ1-42 exists in NCI [168], and mixed cohorts of NCI and AD [169,170], with no correlation between PiB PET and CSF tau [171]. Longitudinal studies suggested that amyloid PET may be more sensitive than CSF Aβ1-42 in identifying MCI cases that will convert to AD [172,173].
Although the two pathological hallmarks of Alzheimer’s disease (AD), senile plaques composed of amyloid-β (Aβ) peptides and neurofibrillary tangles (NFTs) consisting of hyperphosphorylated tau, have been studied extensively in postmortem AD and relevant animal and cellular models, the pathogenesis of AD remains unknown, particularly in the early stages of the disease where therapies presumably would be most effective. We and others have demonstrated that Aβ plaques and NFTs are present in varying degrees before the onset and throughout the progression of dementia. In this regard, aged people with no cognitive impairment (NCI), mild cognitive impairment (MCI, a presumed prodromal AD transitional state, and AD all present at autopsy with varying levels of pathological hallmarks. Cognitive decline, a requisite for the clinical diagnosis of dementia associated with AD, generally correlates better with NFTs than Aβ plaques. However, correlations are even higher between cognitive decline and synaptic loss. In this review, we illustrate relevant clinical pathological research in preclinical AD and throughout the progression of dementia in several areas including Aβ and tau pathobiology, single population expression profiling of vulnerable hippocampal and basal forebrain neurons, neuroplasticity, neuroimaging, cerebrospinal fluid (CSF) biomarker studies and their correlation with antemortem cognitive endpoints. In each of these areas, we provide evidence for the importance of studying the pathological hallmarks of AD not in isolation, but rather in conjunction with other molecular, cellular, and imaging markers to provide a more systematic and comprehensive assessment of the multiple changes that occur during the transition from NCI to MCI to frank AD.
Individual estimates of age at detectable amyloid onset for risk factor assessment
2016, Alzheimer's and Dementia
Citation Excerpt :
Cerebral amyloid-beta (Aβ) deposition is the defining characteristic of preclinical stages of Alzheimer's disease (AD) [1] and begins years before cognitive symptoms are evident [2]. The apolipoprotein E (APOE) ε4 allele is the most influential known genetic risk factor for late-onset AD [3,4] and is associated with higher cortical Aβ burden in cognitively normal individuals [5–23]. Age at onset of AD is a phenotype of great clinical interest, as delaying onset will decrease population prevalence and disease burden [24].
Individualized estimates of age at detectable amyloid-beta (Aβ) accumulation, distinct from amyloid positivity, allow for analysis of onset age of Aβ accumulation as an outcome measure to understand risk factors.
Using longitudinal Pittsburgh compound B (PiB) positron emission tomography data from Baltimore Longitudinal Study of Aging, we estimated the age at which each PiB+ individual began accumulating Aβ. We used survival analysis methods to quantify risk of accumulating Aβ and differences in onset age of Aβ accumulation in relation to APOE ε4 status and sex among 36 APOE ε4 carriers and 83 noncarriers.
Age at onset of Aβ accumulation for the APOE ε4− and ε4+ groups was 73.1 and 60.7, respectively. APOE ε4 positivity conferred a threefold risk of accumulating Aβ after adjusting for sex and education.
Estimation of onset age of amyloid accumulation may help gauge treatment efficacy in interventions to delay symptom onset in Alzheimer's disease.
Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers
2013, Revue Neurologique
Citation Excerpt :
APOE4 has even been reported to be the best predictor of the presence of amyloid in the brain of healthy elderly amongst age, sex, APOE genotype, family history, or cognitive performance. Yet, it is interesting to note that one study reported that PiB binding has a high heritability, and 74% of the heritable component cannot be explained by APOE4 genotype (Hinrichs et al., 2010). Results are partly discrepant, especially regarding the effect of APOE4 on brain structure.
The E4 allele of the apolipoprotein E (APOE4) is the major known genetic risk factor for Alzheimer's disease (AD), with a dramatic increase in the risk of developing AD as the number of APOE4 alleles increases from 0 to 2. For this reason, asymptomatic APOE4 carriers as a group offer a great opportunity to search for the presence of early biomarkers for AD. The present article reviews neuroimaging studies on APOE4 carriers, focusing on cognitively normal individuals and on the main neuroimaging biomarkers for AD, i.e. atrophy with structural MRI, hypometabolism with FDG-PET, and amyloid deposition with amyloid-PET imaging.
There are a great number of studies on the effect of APOE4 on brain structures, and they tend to show significant atrophy in APOE4 carriers compared to non-carriers especially in regions susceptible to AD pathology such as the hippocampus. However, results are rather discrepant which suggests that the effect of APOE4 on brain structure is subtle. As for FDG-PET metabolism, the few available studies show decreased metabolism, again especially in AD-sensitive regions such as posterior associative parietal areas, with a dose-dependent effect (i.e. worsening as the number of APOE4 alleles increases). Finally, there is a unanimous and major effect of APOE4 on amyloid deposition with an increase in Aβ load as the number of APOE4 alleles increases and a decrease in the age of predicted amyloid-positivity in APOE4 carriers. This graded effect of APOE4 on atrophy, hypometabolism, and amyloid deposition is consistent with multimodal neuroimaging studies suggestive of a predominant effect of APOE4 on amyloid rather than tau-related injury and on brain metabolism rather than brain structure. Neuroimaging studies also suggest that APOE4 effects may be mediated by both Aβ-dependent and Aβ-independent pathological processes. This contradicts the view that Aβ pathology is a necessary upstream event to neuronal injury in AD.
Future studies should tell whether the mechanisms and sequences evidenced in carriers are comparable to those found in non-carriers, but it is likely that APOE4 not only influences the risk for AD, but also modulates the pathophysiological cascade. Altogether, APOE4 carriers offer a great opportunity to investigate brain changes in the asymptomatic stages of AD and to further our understanding of the pathophysiology of the disease, although precaution is needed for interpretation in AD at large.
L’allèle E4 de l’apolipoprotéine E (APOE4) est le plus important facteur de risque génétique pour la maladie d’Alzheimer (MA), avec une augmentation dramatique de ce risque lorsque le nombre d’allèles APOE4 augmente. Les porteurs asymptomatiques de l’allèle APOE4 représentent donc une population particulièrement intéressante pour évaluer, à l’échelle du groupe, la présence de biomarqueurs précoces de la MA. La présente revue, qui correspond à une conférence donnée dans le cadre des Journées Internationales de la Société française de neurologie, rapporte les résultats des études d’imagerie chez les porteurs APOE4 en se focalisant uniquement sur les sujets asymptomatiques et en considérant essentiellement les techniques d’imagerie les plus reconnues : l’IRM structurale pour étudier l’atrophie, la TEP-FDG pour le métabolisme et l’imagerie TEP des dépôts amyloïdes.
De très nombreuses études ont évalué les effets de l’APOE4 sur la structure cérébrale. Les résultats sont très divergents, même s’ils suggèrent dans l’ensemble un effet subtile dans le sens d’une diminution de volume dans les régions les plus sensibles à la MA telles que l’hippocampe. Les rares études en TEP-FDG indiquent une baisse du métabolisme là encore dans les régions altérées précocement dans la MA comme le cortex associatif pariétal postérieur, avec un effet dose-dépendant (i.e. fonction du nombre d’allèles APOE4). Enfin, l’effet sur les dépôts amyloïdes est unanime et massif, indiquant une augmentation dose-dépendante chez les porteurs APOE4, et une diminution de l’âge prédit de positivité pour l’amyloïde chez les porteurs. Cet effet graduel de l’APOE4 sur l’atrophie, l’hypométabolisme, puis les dépôts amyloïdes est retrouvé dans les études multimodales qui suggèrent un effet prédominant de l’APOE4 sur les processus amyloïde-dépendants plutôt que tau-dépendants, et sur le métabolisme plutôt que sur la structure. Ces études multimodales, y compris celles réalisées au moyen d’autres techniques d’imagerie, suggèrent également que l’effet de l’APOE4 pourrait être sous-tendu par des processus Aβ-dépendants et Aβ-indépendants.
D’autres études devront être conduites pour déterminer si les mécanismes et la séquence d’événements sont les mêmes chez les porteurs et chez les non-porteurs, mais il semble que l’APOE4 n’influence pas uniquement le risque mais pourrait également modifier la cascade d’événements conduisant à la MA. Dans l’ensemble, ces études soulignent l’intérêt des populations APOE4 pour évaluer les changements cérébraux survenant aux stades les plus précoces de la MA, même si toute généralisation des résultats chez les APOE4 à la MA en général doit être considérée avec prudence.
Finding risk in all the right places
2013, Neuron
Citation Excerpt :
In this issue of Neuron, Cruchaga et al. (2013) describe an alternate approach, leveraging the power of genetics to find variability that modulates a disease-relevant endophenotype, and in turn using these results to identify risk alleles for AD. The notion of endophenotype as a route to understanding the basis of disease is one that has received considerable attention in recent years, particularly in the field of psychiatric genetics (Cruchaga et al., 2012; Hinrichs et al., 2010; Kauwe et al., 2007, 2008). The concept is simple and centers on addressing a problem that is particularly acute in late onset disorders: the temporal distance between initiation of a disease process and clinical presentation is a long one.
PET amyloid-beta imaging in preclinical Alzheimer's disease
2012, Biochimica et Biophysica Acta - Molecular Basis of Disease
Citation Excerpt :
Various ROIs and global means of representative cortical regions are used by different centers. In our university, we define mean cortical binding potential (MCBP) calculated from the mean of the binding potential values in the prefrontal cortex, gyrus rectus, lateral temporal, and precuneus regions [42,84,96,97]. Others use mean cortical DVR averaged from frontal, anterior cingulate, precuneus, lateral temporal, and parietal cortex and striatum [94] or calculate mean DVR from manually drawn orbitofrontal, prefrontal, superior frontal, parietal, lateral temporal, occipital, and anterior and posterior cingulate regions [98].
Alzheimer's disease (AD) is the leading cause of dementia, accounting for 60–70% of all cases [Hebert et al., 2003, 1]. The need for effective therapies for AD is great. Current approaches, including cholinesterase inhibitors and N-methyl-d-aspartate (NMDA) receptor antagonists, are symptomatic treatments for AD but do not prevent disease progression. Many diagnostic and therapeutic approaches to AD are currently changing due to the knowledge that underlying pathology starts 10 to 20 years before clinical signs of dementia appear [Holtzman et al., 2011, 2]. New therapies which focus on prevention or delay of the onset or cognitive symptoms are needed. Recent advances in the identification of AD biomarkers now make it possible to detect AD pathology in the preclinical stage of the disease, in cognitively normal (CN) individuals; this biomarker data should be used in the selection of high-risk populations for clinical trials. In vivo visualization of AD neuropathology and biological, biochemical or physiological confirmation of the effects of treatment likely will substantially improve development of novel pharmaceuticals. Positron emission tomography (PET) is the leading neuroimaging tool to detect and provide quantitative measures of AD amyloid pathology in vivo at the early stages and follow its course longitudinally. This article is part of a Special Issue entitled: Imaging Brain Aging and Neurodegenerative disease.
Amyloid PET: Its diagnostic potential compared to FDG
2011, Medecine Nucleaire
Amyloid PET using high-affinity ligands for fibrillary amyloid is providing high specificity and sensitivity for detection of Alzheimer's disease (AD) even before onset of dementia. Most current published data have been acquired using 11C-Pittsburgh Compound B (PIB). However, due to the extremely short half-life of 11C, PIB is available only in some research laboratories. This limitation will be overcome by 18F-labeled ligands which are currently undergoing formal clinical trials as amyloid imaging agents and are expected to become commercially available for clinical use in the near future. Compared to FDG, which demonstrates regional metabolic deficits in AD and late-stage mild cognitive impairment (MCI), amyloid imaging is expected to provide higher sensitivity for early detection of AD. By detecting amyloid, it is providing information that is complementary to clinical symptoms, while FDG-PET is more closely related to dementia severity and cognitive symptoms. Current data suggest that a negative amyloid PET scan is likely to rule out AD with more than 90% certainty, while a positive scan in a dementia patient or a patient with amnestic MCI indicates a very high likelihood of AD. There is still uncertainty about the clinical significance of positive amyloid scans in elderly normal controls (10 to 40% depending on age and selection criteria).
L’imagerie TEP des plaques amyloïdes à l’aide de ligands de haute affinité pour les plaques amyloïdes fibrillaires apporte une sensibilité et une spécificité élevée à la détection de la maladie d’Alzheimer (MA) avant même l’apparition de la démence. La plupart des résultats publiés ont été obtenus en utilisant le composé B Pittsburgh marqué au 11C (PIB). Cependant, en raison de la période extrêmement courte du 11C, le PIB n’est disponible que dans quelques laboratoires de recherche. Cette limitation pourra être dépassée grâce aux ligands marqués au fluor18. Ces ligands font actuellement l’objet d’essais cliniques et leur commercialisation pour l’utilisation clinique est attendue dans un proche avenir. En comparaison avec le FDG, qui montre la réduction régionale du métabolisme dans la MA et dans les stades avancés du mild cognitive impairment (MCI), on attend de l’imagerie des plaques amyloïdes, une plus grande sensibilité pour le diagnostic précoce de la MA. L’imagerie des plaques amyloïdes apporte une information complémentaire des symptômes cliniques, tandis que la TEP-FDG est plus étroitement reliée à la sévérité de la démence et des symptômes cognitifs. Les résultats récents suggèrent qu’une scintigraphie des plaques amyloïdes négative permet d’écarter l’existence d’une MA avec une certitude de 90 %, alors qu’une scintigraphie positive chez un patient dément, ou chez un patient avec une MCI amnésique, indique une très forte probabilité de MA. Il y a encore des incertitudes sur la signification clinique d’une scintigraphie des plaque amyloïdes positive chez un sujet âgé contrôle (10 à 40 % selon l’âge et les critères de sélection).

View all citing articles on Scopus

View full text

Brief ReportCortical Binding of Pittsburgh Compound B, an Endophenotype for Genetic Studies of Alzheimer's Disease

Background

Methods

Results

Conclusions

Section snippets

Subjects

Family Sample

Discussion

Am J Hum Genet

Neuropsychologia

Neuroimage

Molecular genetics of Alzheimer's disease

Curr Psychiatry Rep

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer's disease and relation to apolipoprotein E genotype

Arch Neurol

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer's disease

JAMA

Synthesis and evaluation of 11c-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents

J Med Chem

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

Ann Neurol

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans

Ann Neurol

(11C)PIB in a nondemented population: Potential antecedent marker of Alzheimer's disease

Neurology

Brief Report
Cortical Binding of Pittsburgh Compound B, an Endophenotype for Genetic Studies of Alzheimer's Disease